The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding
Open accessAbstract
The aim of this study was to develop a treatment protocol for 225Ac-PSMA-617 α-radiation therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with prostate-specific membrane antigen (PSMA)–positive tumor phenotype. Methods: A dosimetry estimate was calculated on the basis of time–activity curves derived from serially obtained 177Lu-PSMA-617 scans extrapolated to the physical half-life of 225Ac, assuming instant decay of unstable daughter nuclides. Salvage therapies empirically conducted with 50 (n = 4), 100 (n = 4), 150 (n = 2), and 200 kBq/kg (n = 4) of 225Ac-PSMA-617 were evaluated retrospectively regarding toxicity and treatment response. Eight of 14 patients received further cycles in either 2- or 4-mo intervals with identical or deescalated activities. Results: Dosimetry estimates for 1 MBq of 225Ac-PSMA-617 assuming a relative biologic effectiveness of 5 revealed mean doses of 2.3 Sv for salivary glands, 0.7 Sv for kidneys, and 0.05 Sv for red marrow that are composed of 99.4% α, 0.5% β, and 0.1% photon radiation, respectively. In clinical application, severe xerostomia became the dose-limiting toxicity if treatment activity exceeded 100 kBq/kg per cycle. At 100 kBq/kg, the duration of prostate-specific antigen decline was less than 4 mo, but if therapy was repeated every 2 mo patients experienced additive antitumor effects. Treatment activities of 50 kBq/kg were without toxicity but induced insufficient antitumor response in these high-tumor-burden patients. Remarkable antitumor activity by means of objective radiologic response or tumor marker decline was observed in 9 of 11 evaluable patients. Conclusion: For advanced-stage patients, a treatment activity of 100 kBq/kg of 225Ac-PSMA-617 per cycle repeated every 8 wk presents a reasonable trade-off between toxicity and biochemical response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, current clinical TAT research relies greatly on indirect approximation by extrapolating pre-existing 177Lu-labeled pharmaceuticals (84, 112, 113).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [84]
In the citing paper
“However, a low probability of γ-emission and overlapping Bremsstrahlung due to β-emitters in the 225Ac decay chain preclude simultaneous treatment and dosimetry measurement in a clinical setting (84).”
From Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists (2022) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408
(1997) · PubMed · Cited by 1,541
Stabin, M. G., Sparks, R. B., & Crowe, E. A. (2005) · PubMed · Cited by 1,340
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Self-citationRahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 861
Self-citationKratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Self-citationBenešová, M., Schäfer, M. K.-H., Bauder‐Wüst, U., Afshar‐Oromieh, A., Kratochwil, C., Mier, W., Haberkorn, U., Kopka, K., & Eder, M. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.147413 · Cited by 621
Self-citationGiesel, F. L., Hadaschik, B. A., Cardinale, J., Radtke, J. P., Vinsensia, M., Lehnert, W., Kesch, C. V., Tolstov, Y. L., Singer, S., Grabe, N., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3573-4 · Cited by 595
Self-citationSgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552
Tumor therapy with targeted atomic nanogenerators.
McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., et al. (2001) · Science · doi:10.1126/science.1064126 · Cited by 501
Cited by
Sorted by citations
Items 201–300 of 504
Coll, R. P., Bright, S. J., Martinus, D. K. J., Georgiou, D. K., Sawakuchi, G. O., & Manning, H. C. (2023) · Molecular Imaging and Biology · doi:10.1007/s11307-023-01857-y · Cited by 30
Bobba, K. N., Bidkar, A. P., Wadhwa, A., Meher, N., Drona, S., Sorlin, A. M., Bidlingmaier, S. M., Zhang, L., Wilson, D. M., Chan, E., et al. (2024) · Theranostics · doi:10.7150/thno.92742 · Cited by 29
Targeted Alpha Therapy and Nanocarrier Approach
Silindir‐Gunay, M., Karpuz, M., & Özer, A. Y. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.3213 · Cited by 29
Felber, V. B., Valentin, M. A., & Wester, H. (2021) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-021-00124-1 · Cited by 29
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer
Staniszewska, M., Iking, J., Lückerath, K., Hadaschik, B. A., Herrmann, K., Ferdinandus, J., & Fendler, W. P. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.03.009 · Cited by 31
Hammer, S., Schlicker, A., Zitzmann-Kolbe, S., Baumgart, S. J., Hagemann, U. B., Scholz, A., Haendler, B., Lejeune, P., Karlsson, J., Ellingsen, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0342 · Cited by 29
Isolation of 212Pb from natural thorium for targeted alpha-therapy
Chen, J., Xu, M., Liu, Y., Duan, D., Han, Y., & Liu, Z. (2022) · Chinese Chemical Letters · doi:10.1016/j.cclet.2022.02.012 · Cited by 28
Li, Z., Benabdallah, N., Abou, D. S., Baumann, B. C., Dehdashti, F., Ballard, D. H., Liu, J., Jammalamadaka, U. M., Laforest, R. A., Wahl, R. L., et al. (2022) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2022.3175435 · Cited by 28
Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain
Vornov, J. J., Peters, D. E., Nedelcovych, M., Hollinger, K. R., Rais, R., & Slusher, B. S. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02909-y · Cited by 28
Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer
Lückerath, K., Stuparu, A. D., Liu, W., Kim, W., Radu, C. G., Mona, C. E., Calais, J., Rettig, M. B., Reiter, R. E., Czernin, J. G., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.207704 · Cited by 27
Beyond the Barrier: Targeted Radionuclide Therapy in Brain Tumors and Metastases
Puttemans, J., Lahoutte, T., D’Huyvetter, M., & Devoogdt, N. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080376 · Cited by 27
Banerjee, S. R., Kumar, V., Lisok, A., Plyku, D., Nováková, Z., Brummet, M. E., Wharram, B. L., Bařinka, C., Hobbs, R. F., & Pomper, M. G. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.214403 · Cited by 27
An Impressive Approach in Nuclear Medicine
Vahidfar, N., Eppard, E., Farzanehfar, S., Yordanova, A., Fallahpoor, M., & Ahmadzadehfar, H. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.03.011 · Cited by 27
Schatz, C. A., Zitzmann-Kolbe, S., Moen, I. N., Klotz, M., Nair, S., Stargard, S., Bjerke, R. M., Biseth, K. W., Feng, Y. Z., Indrevoll, B., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3746 · Cited by 27
Bicak, M., Lückerath, K., Kalidindi, T. M., Phelps, M. E., Strand, S., Morris, M. J., Radu, C. G., Damoiseaux, R. D., Peltola, M. T., Peekhaus, N. T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918744117 · Cited by 27
Theoretical Study of Actinide(III)-DOTA Complexes
Kovács, A. (2021) · ACS Omega · doi:10.1021/acsomega.1c01292 · Cited by 26
Unterrainer, L. M., Beyer, L., Zacherl, M. J., Gildehaus, F. J., Todica, A. S., Kunte, S. C., Holzgreve, A., Sheikh, G. T., Herlemann, A., Casuscelli, J., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10050946 · Cited by 25
Challenges and opportunities in developing Actinium-225 radiopharmaceuticals
Dhiman, D., Vatsa, R., & Sood, A. K. (2022) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001594 · Cited by 25
Individualization of Radionuclide Therapies: Challenges and Prospects
Piwowarska-Bilska, H., Kurkowska, S., & Birkenfeld, B. (2022) · Cancers · doi:10.3390/cancers14143418 · Cited by 26
Evaluation of [225Ac]Ac-DOTA-anti-VLA-4 for targeted alpha therapy of metastatic melanoma
Cortez, A. G., Josefsson, A., McCarty, G. W., Shtekler, A., Rao, A., Austin, Z., & Nedrow, J. R. (2020) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2020.07.006 · Cited by 26
van der Sar, E. C. A., Kühr, A. J. S., Ebbers, S. C., Henderson, A., de Keizer, B., Lam, M. G. E. H., & Braat, A. J. A. T. (2022) · Biomedicines · doi:10.3390/biomedicines10071575 · Cited by 26
Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma
Makvandi, M., Samanta, M., Martorano, P., Lee, H., Gitto, S. B., Patel, K., Groff, D., Pogoriler, J. E., Martínez, D., Riad, A., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-04209-8 · Cited by 24
Vatsa, R., Sood, A., Vadi, S. K., Das, C. K., Kaur, K., Parmar, M., & Mittal, B. R. (2020) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000003031 · Cited by 23
Actinium-225 in Targeted Alpha Therapy
Rahman, A. K. M. R., Babu, M. H., Ovi, M. K., Zilani, M. M., Eithu, I. S., & Chakraborty, A. (2024) · Journal of Medical Physics · doi:10.4103/jmp.jmp_22_24 · Cited by 25
Berner, K., Hernes, E., Kvassheim, M., Revheim, M.-E. R., Bastiansen, J., Selboe, S., Bakken, C. L., Grønningsæter, S. R., Bruland, Ø. S., Larsen, R. H., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269299 · Cited by 23
PET Radiopharmaceuticals: What’s New, What’s Reimbursed, and What’s Next?
Clarke, B. (2018) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.117.205021 · Cited by 23
Kristiansson, A., Örbom, A., Timmermand, O. V., Ahlstedt, J., Strand, S., & Åkerström, B. (2021) · Antioxidants · doi:10.3390/antiox10081271 · Cited by 23
Calais, J., Eulau, S. M., Gardner, L., Hauke, R. J., Kendi, A. T., Shore, N. D., & Zhao, S. Q. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102524 · Cited by 24
DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay
Schmeiser, H. H., Muehlbauer, K., Mier, W., Baranski, A.-C., Neels, O. C., Dimitrakopoulou‐Strauss, A., Schmezer, P., Kratochwil, C., Bruchertseifer, F., Morgenstern, A., et al. (2019) · Mutagenesis · doi:10.1093/mutage/gez007 · Cited by 23
Self-citationA GATE simulation study for dosimetry in cancer cell and micrometastasis from the 225Ac decay chain
Koniar, H., Miller, C., Rahmim, A., Schaffer, P. C., & Uribe, C. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00564-5 · Cited by 22
Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals
Diao, W., Cai, H., Chen, L., Jin, X., Liao, X., & Jia, Z. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190201100739 · Cited by 22
Non-FDG PET/CT in Diagnostic Oncology: a pictorial review
Giammarile, F., Castellucci, P., Dierckx, R., Lobato, E. E., Farsad, M., Hustinx, R., Jalilian, A. R., Pellet, O., Rossi, S., & Páez, D. (2019) · European Journal of Hybrid Imaging · doi:10.1186/s41824-019-0066-2 · Cited by 26
Poty, S., Mandleywala, K., O’Neill, E. S., Knight, J. C., Cornelissen, B. T., & Lewis, J. S. (2020) · Theranostics · doi:10.7150/thno.44772 · Cited by 22
Sudo, H., Tsuji, A. B., Sugyo, A., Kaneko, M. K., Kato, Y., Nagatsu, K., Suzuki, H., & Higashi, T. (2021) · Cells · doi:10.3390/cells10102503 · Cited by 23
Lee, H. (2022) · Molecular Imaging and Radionuclide Therapy · doi:10.4274/mirt.galenos.2021.63308 · Cited by 22
Activity quantification and dosimetry in radiopharmaceutical therapy with reference to 177Lutetium
Ramonaheng, K., Qebetu, M., Ndlovu, H., Swanepoel, C., Smith, L., Mdanda, S., Mdlophane, A. H., & Sathekge, M. M. (2024) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2024.1355912 · Cited by 23
Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies
Jadvar, H. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2019.3340 · Cited by 21
The five “W”s and “How” of Targeted Alpha Therapy: Why? Who? What? Where? When? and How?
Sollini, M., Marzo, K., Chiti, A., & Kirienko, M. (2020) · RENDICONTI LINCEI · doi:10.1007/s12210-020-00900-2 · Cited by 21
Veach, D. R., Storey, C. M., Lückerath, K., Braun, K., von Bodman, C., Lamminmäki, U., Kalidindi, T. M., Strand, S., Strand, J., Altai, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3614 · Cited by 21
Kessel, K., Bernemann, C., Bögemann, M., & Rahbar, K. (2021) · Cancers · doi:10.3390/cancers13143556 · Cited by 21
PSMA-targeted low-molecular double conjugates for diagnostics and therapy
Petrov, S. A., Zyk, N. Y., Machulkin, A. E., Beloglazkina, E. K., & Majouga, A. G. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113752 · Cited by 21
225Ac-Labeled Antibody for Fibroblast Activation Protein-Targeted Alpha Therapy
Song, H., Xu, M., Cai, J., Chen, J., Liu, Y., Su, Q., Li, Z., & Liu, Z. (2023) · Chemical & Biomedical Imaging · doi:10.1021/cbmi.3c00067 · Cited by 21
Chen, M., Cai, L., Xiang, Y., Zhong, L., & Shi, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106889 · Cited by 21
Babeker, H., Njotu, F. N., Ketchemen, J. P., Monzer, A., Tikum, A. F., Doroudi, A., Nwangele, E., Uppalapati, M., & Fonge, H. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.268387 · Cited by 20
The Impact of Lifestyle on Prostate Cancer: A Road to the Discovery of New Biomarkers
Leitão, C., Matos, B., Roque, F., Herdeiro, M. T., & Fardilha, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102925 · Cited by 20
Castillo, D., Saint‐Hubert, M. D., Ahenkorah, S., Vargas, C. S., Ooms, M., Struelens, L., & Koole, M. J. B. (2022) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-022-00174-z · Cited by 20
Pruis, I. J., van Doormaal, P., Balvers, R. K., van den Bent, M. J., Harteveld, A. A., de Jong, L. C., Konijnenberg, M., Segbers, M., Valkema, R., Verburg, F. A., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105068 · Cited by 21
Shooli, H., Nemati, R., Ahmadzadehfar, H., Aboian, M., Jafari, E., Jokar, N., Nabipour, I., Dadgar, H., Gholamrezanezhad, A., Larvie, M., et al. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.03.005 · Cited by 20
Liolios, C. C., Sachpekidis, C., Schäfer, M. K.-H., & Kopka, K. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3749 · Cited by 19
Rodríguez, J. C., Huh, Y., Gullberg, G. T., & Seo, Y. (2022) · IEEE Transactions on Radiation and Plasma Medical Sciences · doi:10.1109/trpms.2022.3166116 · Cited by 19
Schumann, S., Eberlein, U., Müller, J., Scherthan, H., & Laßmann, M. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0422-4 · Cited by 19
Vahidfar, N., Fallahpoor, M., Farzanehfar, S., Divband, G., & Ahmadzadehfar, H. (2019) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-019-06800-6 · Cited by 19
Alsadi, R., Djekidel, M., Bouhali, O., & O’Doherty, J. (2022) · Frontiers in Physics · doi:10.3389/fphy.2022.940677 · Cited by 21
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Ayzman, A., Pachynski, R. K., & Reimers, M. A. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01317-5 · Cited by 18
“For example, novel RLTs such as Actinium-225 PSMA-617 are being tested to overcome resistance to Lutetium-based therapies [6, 7].”
Yoshimoto, M., Yoshii, Y., Matsumoto, H., Shinada, M., Takahashi, M., Igarashi, C., Hihara, F., Tachibana, T., Doi, A., Higashi, T., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101706 · Cited by 18
Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
Szponar, P., Petrasz, P., Brzeźniakiewicz‐Janus, K., Drewa, T. A., Zorga, P., & Adamowicz, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1239118 · Cited by 18
Dalm, S. U., Duan, H., & Iagaru, A. H. (2024) · PET Clinics · doi:10.1016/j.cpet.2024.03.004 · Cited by 18
A third generation PSMA-targeted agent [211At]YF2: Synthesis and in vivo evaluation
Feng, Y., Meshaw, R. L., Finch, S. W., Zheng, Y., Minn, I., Vaidyanathan, G., Pomper, M. G., & Zalutsky, M. R. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108916 · Cited by 18
Design of 225Ac-PSMA for targeted alpha therapy in prostate cancer
Kairemo, K., Kgatle, M. M., Bruchertseifer, F., Morgernstern, A., & Sathekge, M. M. (2024) · Annals of Translational Medicine · doi:10.21037/atm-23-1842 · Cited by 18
Self-citationBiogeochemistry of Actinides: Recent Progress and Perspective
Deblonde, G. J. ‐. (2024) · ACS Environmental Au · doi:10.1021/acsenvironau.4c00037 · Cited by 19
Tsai, W. K., Zettlitz, K. A., Dahlbom, M. L., Reiter, R. E., & Wu, A. M. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01518-4 · Cited by 18
A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling
Ermolaev, S. V., Skasyrskaya, A. K., & Vasiliev, A. N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060914 · Cited by 18
Muralidhar, A., Potluri, H. K., Jaiswal, T., & McNeel, D. G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010252 · Cited by 17
Ceuppens, H., Antunes, A. R. P., Navarro, L., Ertveldt, T., Berdal, M., Nagachinta, S., Ridder, K. D., Lahoutte, T., Keyaerts, M., Devoogdt, N., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06914-4 · Cited by 17
Development of Targeted Alpha Therapy from Bench to Bedside
Morgenstern, A., & Bruchertseifer, F. (2019) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2019.06.046 · Cited by 17
Self-citationQuantitative SPECT/CT for Dosimetry of Peptide Receptor Radionuclide Therapy
Kennedy, J. A., Chicheportiche, A., & Keidar, Z. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2021.11.004 · Cited by 17
Radiation dosimetry and efficacy of an 89Zr/225Ac-labeled humanized anti-MUC5AC antibody
Nakata, N., Kobashi, N., Okumura, Y., Sato, M., Matono, M., Otsuki, K., Tanaka, A., & Hayashi, A. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.02.003 · Cited by 19
Mattana, F., Muraglia, L., Barone, A., Colandrea, M., Saker Diffalah, Y., Provera, S., Cascio, A. S., Omodeo Salè, E., & Ceci, F. (2024) · Cancers · doi:10.3390/cancers16091643 · Cited by 16
Yu, H., Lv, J., Hu, P., Chen, S., & Shi, H. (2021) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001506 · Cited by 16
Prostate specific membrane antigen binding radiopharmaceuticals: Current data and new concepts
Sartor, O. A., & Baghian, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1060922 · Cited by 16
Malaspina, S., Giorgi, U. D., Kemppainen, J., Sole, A. D., & Paganelli, G. (2018) · La radiologia medica · doi:10.1007/s11547-018-0929-9 · Cited by 16
Modelling the internalisation process of prostate cancer cells for PSMA-specific ligands
Winter, G., Vogt, A., Jiménez‐Franco, L. D., Rinscheid, A., Yousefzadeh‐Nowshahr, E., Solbach, C., Beer, A. J., Glatting, G., & Kletting, P. (2019) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2019.05.003 · Cited by 16
Tichacek, C. J., Budzevich, M. M., Wadas, T. J., Morse, D. L., & Moros, E. G. (2019) · Molecules · doi:10.3390/molecules24183397 · Cited by 16
Novel Agents and Future Perspectives on Theranostics
Sólnes, L. B., Shokeen, M., & Pandit-Taskar, N. D. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2020.07.010 · Cited by 16
Radiopharmaceuticals Based on Alpha Emitters: Preparation, Properties, and Application
Garashchenko, B. L., Корсакова, В. А., & Yakovlev, R. Y. (2018) · Physics of Atomic Nuclei · doi:10.1134/s1063778818100071 · Cited by 16
Radionuclide-Labeled Biomaterials: A Novel Strategy for Tumor-Targeted Therapy
Zhang, S., Zhang, A., Qi, X., Han, Z., Song, L., Zhou, J., Wang, G., Zhu, R., & Li, J. (2025) · Biomimetics · doi:10.3390/biomimetics10060394 · Cited by 17
Widjaja, L., Derlin, T., Roß, T. L., Bengel, F. M., & Werner, R. A. (2021) · The Prostate · doi:10.1002/pros.24250 · Cited by 15
Ling, S. W., van der Veldt, A. A. M., Konijnenberg, M., Segbers, M., Hooijman, E. L., Bruchertseifer, F., Morgenstern, A., de Blois, E., & Brabander, T. (2024) · BMC Cancer · doi:10.1186/s12885-024-11900-y · Cited by 15
Self-citationYaginuma, K., Takahashi, K., Hoshi, S., Joho, T., Shimoyama, S., Hasegawa, N., Hasegawa, K., Zhao, S., Ukon, N., Makabe, S., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06945-x · Cited by 15
The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer
Laudicella, R., Bauckneht, M., Burger, I. A., Cacciola, A., Fanti, S., Farolfi, A., Ficarra, V., Iagaru, A. H., Liberini, V., Pergolizzi, S., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07083-8 · Cited by 16
More α Than β for Prostate Cancer?
Fendler, W. P., & Cutler, C. S. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198333 · Cited by 15
Castillo, D., Saint‐Hubert, M. D., Crabbé, M., Struelens, L., & Koole, M. J. B. (2020) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.20.03266-5 · Cited by 15
Armstrong, W. R., Gafita, A., Zhu, S., Thin, P., Nguyen, K., Alano, R. M., Lira, S., Booker, K. M., Gardner, L., Grogan, T., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.257931 · Cited by 15
Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine
Montemagno, C., & Pagès, G. (2020) · Cancers · doi:10.3390/cancers12040821 · Cited by 15
Rumiantcev, M., Li, W. B., Lindner, S., Liubchenko, G., Resch, S., Bartenstein, P., Ziegler, S. I., Böning, G., & Delker, A. (2023) · EJNMMI Physics · doi:10.1186/s40658-023-00567-2 · Cited by 15
Uygur, E., Sezgın, C., Parlak, Y., Karatay, K. B., Arıkbaşı, B., Avcıbaşı, U., Toklu, T., Barutça, S., Harmanşah, Ç., Sözen, T., et al. (2024) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-024-09809-8 · Cited by 14
Ketchemen, J. P., Njotu, F. N., Babeker, H., Monzer, A., Nwangele, E., Tikum, A. F., Henning, N. W., Hassani, N., Frye, S. A., Perron, R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-1779 · Cited by 14
Beşiroğlu, H., & Kadıhasanoğlu, M. (2025) · The Prostate · doi:10.1002/pros.24857 · Cited by 14
Understanding the biological behavior of lanthanides and actinides through omics approaches
Pallares, R. M., Li, Y., & Abergel, R. J. (2023) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2023.117251 · Cited by 13
Kröcher, A., Folprecht, G., Winzer, R., Sergon, M., Bornhäuser, M., Kotzerke, J., & Brogsitter, C. (2023) · Case Reports in Oncology · doi:10.1159/000533198 · Cited by 13
Brain metastasis: An insight into novel molecular targets for theranostic approaches
Santos, L., Moreira, J. N., Abrunhosa, A., & Gomes, C. M. F. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104377 · Cited by 13
Wondergem, M., van der Zant, F. M., Vlottes, P., & Knol, R. J. J. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.207316 · Cited by 13
68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients
Hoberück, S., Michler, E., Wunderlich, G., Löck, S., Hölscher, T., Froehner, M., Braune, A., Platzek, I., Seppelt, D., Zöphel, K., et al. (2019) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-0990-8898 · Cited by 13
Gabiña, P. M., Roeske, J. C., Mínguez, R., Rodeño, E., & Iturriaga, A. G. (2020) · Physics in Medicine and Biology · doi:10.1088/1361-6560/abbc81 · Cited by 13
Herrera, A. F., Palmer, J. M., Adhikarla, V., Yamauchi, D. M., Poku, E. K., Bading, J. R., Yazaki, P. J., Dandapani, S. V., Mei, M. G., Chen, R., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004981 · Cited by 13
Salerno, D., Howe, A. K., Bhatavdekar, O., Josefsson, A., Pacheco‐Torres, J., Bhujwalla, Z. M., Gabrielson, K. L., & Sofou, S. (2021) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10266 · Cited by 13
PSMA theragnostics for metastatic castration resistant prostate cancer
Hong, S., Guja, K. E., & Iagaru, A. H. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101438 · Cited by 13
Cheng, L., Yang, T., Zhang, J., Gao, F., Yang, L., & Tao, W. (2023) · Korean Journal of Radiology · doi:10.3348/kjr.2022.1002 · Cited by 13
Nawar, M. F., Selim, A. A., Essa, B. M., El-Daoushy, A. F., Swidan, M. M., Chambers, C., Al-Qahtani, M. H., Smith, C. J., & Sakr, T. M. (2025) · Cancers · doi:10.3390/cancers17183055 · Cited by 12
Potent candidates for Targeted Alpha Therapy (TAT)
Filosofov, D. V., Baimukhanova, A., Khushvaktov, J., Kurakina, E. S., & Radchenko, V. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.109027 · Cited by 12
Metadata
- Authors
- Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A.
- Affiliations
- University Hospital Heidelberg (DE)
- European Commission (BE)
- ABX-CRO Advanced Pharmaceutical Services (Germany) (DE)
- Pathologisches Institut (DE)
- German Cancer Research Center (DE)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2017-04-13
- Volume
- 58
- Issue
- 10
- Pages
- 1624-1631
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2606187374
- Cited by
- 505
- References
- 31
- Citations by year
- 2026: 35 · 2025: 60 · 2024: 48 · 2023: 36 · 2022: 53 · 2021: 83 · 2020: 57 · 2019: 61 · 2018: 57 · 2017: 14
- FWCI
- 39.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Joint Research Centre (European Commission) (submittedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- metastatic castration-resistant prostate cancer, dosimetry, 177Lu-PSMA-617, xerostomia, salvage therapy, PSA response, treatment toxicity
- MeSH terms
- Actinium, Aged, Alpha Particles, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Male, Middle Aged, Neoplasm Metastasis, Radiometry, Radiotherapy Dosage, Prostate-Specific Antigen, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
